Advances in engineered bacteria vaccines for enhancing anti-cancer immunity

被引：1
|
作者：
Liu, Wu [1 ]
Chen, Wenjing [2 ]
Cai, Yujie [2 ]
Tang, Yanhua [3 ]
Chen, Tingtao [1 ,4 ,5 ]
机构：
[1] Nanchang Univ, Affiliated Hosp 2, Jiangxi Med Coll, Nanchang 330008, Jiangxi, Peoples R China
[2] Nanchang Univ, Jiangxi Med Coll, Sch Pharm, Nanchang 330008, Jiangxi, Peoples R China
[3] Nanchang Univ, Affiliated Hosp 2, Jiangxi Med Coll, Dept Cardiovasc Surg, 1 Minde Rd, Nanchang 330008, Jiangxi, Peoples R China
[4] Nanchang Univ, Jiangxi Med Coll, MOE Basic Res & Innovat Ctr Targeted Therapeut Sol, Sch Pharm,Jiangxi Prov Key Lab Bioengn Drugs, Nanchang 330031, Jiangxi, Peoples R China
[5] Nanchang Univ, Inst Translat Med, Jiangxi Med Coll, Natl Engn Res Ctr Bioengn Drugs & Technol, 1299 Xuefu Ave, Nanchang 330031, Jiangxi, Peoples R China
来源：
MICROBIOME RESEARCH REPORTS | 2025年 / 4卷 / 01期
关键词：
Engineered bacteria; antitumor; neoantigenic; immunotherapy;
D O I：
10.20517/mrr.2024.75
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Advances in synthetic biology have enabled the development of tumor-targeted live bacterial therapeutics. In a recent study published in Nature, Redenti et al. engineered Escherichia coli Nissle 1917(EcNc Delta lon/Delta ompT/LLO+ nAg), which exploits the advantages of living medicines to deliver arrays of tumor-specific neoantigenic epitope in optimal environments, thereby providing a novel strategy for developing effective and durable cancer immunotherapies.
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Recent advances in the field of anti-cancer immunotherapy
    Neves, Henrique
    Kwok, Hang Fai
    BBA CLINICAL, 2015, 3 : 280 - 288
  • [32] Recent advances in clinical anti-cancer immunotherapy
    Juretic, Antonio
    PERIODICUM BIOLOGORUM, 2014, 116 (04) : 365 - 370
  • [33] Anti-cancer telomerase vaccines are entering the age of maturity
    Filaci, G.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 37 - 37
  • [34] Research Advances on Anti-Cancer Natural Products
    Guo, Meng
    Jin, Jie
    Zhao, Dong
    Rong, Zheng
    Cao, Lu-Qi
    Li, Ai-Hong
    Sun, Xiao-Ying
    Jia, Li-Yi
    Wang, Yin-Di
    Huang, Ling
    Li, Yi-Heng
    He, Zhong-Jing
    Li, Long
    Ma, Rui-Kang
    Lv, Yi-Fan
    Shao, Ke-Ke
    Cao, Hui-Ling
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Advances in oral delivery of anti-cancer prodrugs
    Jain, Amit K.
    Jain, Sanyog
    EXPERT OPINION ON DRUG DELIVERY, 2016, 13 (12) : 1759 - 1775
  • [36] Anti-cancer activity of human gastrointestinal bacteria
    Quazi, Sameer
    MEDICAL ONCOLOGY, 2022, 39 (12)
  • [37] Anti-cancer effect of engineered recombinant interleukin 18
    Saetang, Jirakrit
    Chonpathompikunlert, Pennapa
    Sretrirutchai, Somporn
    Roongsawang, Niran
    Kayasut, Kanita
    Voravuthikunchai, Supayang Piyawan
    Sukketsiri, Wanida
    Tipmanee, Varomyalin
    Sangkhathat, Surasak
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 29 (10): : 1135 - 1143
  • [38] Enhancing anti-cancer immunity through immunogenic cell death: the role of endothelial cells in the tumor microenvironment
    Naessens, Faye
    Demuynck, Robin
    Vershinina, Olga
    Efimova, Iuliia
    Catanzaro, Elena
    Saviuk, Mariia
    van der Meeren, Louis
    Vedunova, Maria
    Coppieters, Frauke
    Ivanchenko, Mikhail
    Krysko, Olga
    Skirtach, Andre
    Krysko, Dmitri
    JOURNAL OF IMMUNOLOGY, 2024, 212 (01):
  • [39] Citrullinated α-enolase is an effective target for anti-cancer immunity
    Cook, Katherine
    Daniels, Ian
    Symonds, Peter
    Pitt, Tracy
    Gijon, Mohamed
    Xue, Wei
    Metheringham, Rachael
    Durrant, Lindy
    Brentville, Victoria
    ONCOIMMUNOLOGY, 2018, 7 (02):
  • [40] From T cell "exhaustion" to anti-cancer immunity
    Verdeil, Gregory
    Marraco, Silvia A. Fuertes
    Murray, Timothy
    Speiser, Daniel E.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2016, 1865 (01): : 49 - 57
12345